Shuichi Sakuda Selected Research

bis(2- ((4- ((4'- (2- hydroxyethoxy)- 2'- methyl(1,1'- biphenyl)- 3- yl)methoxy)phenyl)methyl)- 3,5- dioxo- 1,2,4- oxadiazolidine)

9/2013

Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuichi Sakuda Research Topics

Disease

1	Type 2 Diabetes Mellitus (MODY) 09/2013
1	Insulin Resistance 09/2013

Drug/Important Bio-Agent (IBA)

1	bis(2- ((4- ((4'- (2- hydroxyethoxy)- 2'- methyl(1,1'- biphenyl)- 3- yl)methoxy)phenyl)methyl)- 3,5- dioxo- 1,2,4- oxadiazolidine)IBA 09/2013
1	Insulin (Novolin)FDA Link 09/2013

Therapy/Procedure

1	Therapeutics 09/2013